Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 239.00p on 16-01-2026 at 18:50:07
Change 13.00p 5.75%
Buy 239.00p
Sell 236.00p
Last Trade: Sell 1,495.00 at 239.00p
Day's Volume: 141,476
Last Close: 239.00p
Open: 231.00p
ISIN: KYG4672N1198
Day's Range 230.00p - 239.00p
52wk Range: 187.50p - 292.00p
Market Capitalisation: £2.05b
VWAP: 232.87132p
Shares in Issue: 859.52m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,495 239.00p Uncrossing Trade
16:35:26 - 16-Jan-26
Sell* 100 236.00p Ordinary
16:28:04 - 16-Jan-26
Sell* 224 235.12p Ordinary
16:24:33 - 16-Jan-26
Sell* 700 234.15p Ordinary
16:09:40 - 16-Jan-26
Buy* 5 239.00p SI Trade
16:08:17 - 16-Jan-26
Buy* 1 239.00p Automatic Execution
16:08:17 - 16-Jan-26
Sell* 1 234.10p Ordinary
15:55:20 - 16-Jan-26
Buy* 291 235.00p Automatic Execution
15:32:19 - 16-Jan-26
Buy* 2,850 235.00p Automatic Execution
15:32:19 - 16-Jan-26
Buy* 2,150 235.00p Automatic Execution
15:32:19 - 16-Jan-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
16th Jan 2026 (Fri) 231.00 239.00 230.00 239.00 141,476
15th Jan 2026 (Thu) 225.00 228.00 220.00 226.00 42,581
14th Jan 2026 (Wed) 220.00 225.00 210.00 210.00 8,157
13th Jan 2026 (Tue) 223.00 223.00 219.00 221.00 19,690
12th Jan 2026 (Mon) 225.00 225.00 211.00 225.00 25,444
9th Jan 2026 (Fri) 218.00 218.00 215.00 217.00 9,470
8th Jan 2026 (Thu) 214.00 218.00 214.00 218.00 8,809
7th Jan 2026 (Wed) 210.00 218.00 210.00 214.00 18,547
6th Jan 2026 (Tue) 201.00 211.00 201.00 211.00 9,712
5th Jan 2026 (Mon) 208.00 208.00 195.00 202.00 40,592
2nd Jan 2026 (Fri) 201.00 204.00 200.00 204.00 12,575
1st Jan 2026 (Thu) 208.00 208.00 208.00 208.00 0
31st Dec 2025 (Wed) 199.00 209.00 199.00 208.00 18,573
30th Dec 2025 (Tue) 192.00 198.50 192.00 198.50 34,925
29th Dec 2025 (Mon) 199.00 199.50 193.00 199.00 17,892
26th Dec 2025 (Fri) 196.50 196.50 196.50 196.50 0
25th Dec 2025 (Thu) 196.50 196.50 196.50 196.50 0
24th Dec 2025 (Wed) 196.50 196.50 196.50 196.50 1,030
23rd Dec 2025 (Tue) 198.00 198.00 193.00 193.00 1,777
22nd Dec 2025 (Mon) 196.50 198.00 195.00 198.00 13,824
19th Dec 2025 (Fri) 204.00 204.00 199.00 199.00 29,912
18th Dec 2025 (Thu) 200.00 204.00 200.00 204.00 24,333
17th Dec 2025 (Wed) 200.00 202.00 200.00 202.00 12,753
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
14th Jan 2026 7:00 am RNS-R Publication of Phase III Results in The Lancet
7th Jan 2026 7:00 am RNS-R Positive Topline Results of Phase III Trial
5th Jan 2026 7:00 am RNS-R Surufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 2025 7:00 am RNS Total Voting Rights
31st Dec 2025 7:00 am RNS Total Voting Rights
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

Hutchmed China hails lung cancer trial results published in Lancet

14th Jan 2026 12:06

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,235.29
Change-3.65

Login to your account

Forgot Password?

Not Registered